833 related articles for article (PubMed ID: 24462983)
1. HLA-haploidentical T cell-depleted allogeneic hematopoietic stem cell transplantation in children with Fanconi anemia.
Zecca M; Strocchio L; Pagliara D; Comoli P; Bertaina A; Giorgiani G; Perotti C; Corbella F; Brescia L; Locatelli F
Biol Blood Marrow Transplant; 2014 Apr; 20(4):571-6. PubMed ID: 24462983
[TBL] [Abstract][Full Text] [Related]
2. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
[TBL] [Abstract][Full Text] [Related]
3. The Saudi experience in fludarabine-based conditioning regimens in patients with Fanconi anemia undergoing stem cell transplantation: excellent outcome in recipients of matched related stem cells but not in recipients of unrelated cord blood stem cells.
Ayas M; Al-Seraihi A; El-Solh H; Al-Ahmari A; Khairy A; Aldali A; Markiz S; Siddiqui K; Al-Jefri A
Biol Blood Marrow Transplant; 2012 Apr; 18(4):627-32. PubMed ID: 21871862
[TBL] [Abstract][Full Text] [Related]
4. Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients.
Gonzalez-Vicent M; Perez A; Abad L; Sevilla J; Ramirez M; Diaz MA
J Pediatr Hematol Oncol; 2010 Apr; 32(3):e85-90. PubMed ID: 20216238
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia.
Chaudhury S; Auerbach AD; Kernan NA; Small TN; Prockop SE; Scaradavou A; Heller G; Wolden S; O'Reilly RJ; Boulad F
Br J Haematol; 2008 Mar; 140(6):644-55. PubMed ID: 18302713
[TBL] [Abstract][Full Text] [Related]
6. Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.
Mehta PA; Davies SM; Leemhuis T; Myers K; Kernan NA; Prockop SE; Scaradavou A; O'Reilly RJ; Williams DA; Lehmann L; Guinan E; Margolis D; Baker KS; Lane A; Boulad F
Blood; 2017 Apr; 129(16):2308-2315. PubMed ID: 28179273
[TBL] [Abstract][Full Text] [Related]
7. CD-34 selected hematopoetic stem cell transplantation from HLA identical family members for fanconi anemia.
Balci YI; Akdemir Y; Gumruk F; Cetin M; Arpaci F; Uckan D
Pediatr Blood Cancer; 2008 May; 50(5):1065-7. PubMed ID: 18000858
[TBL] [Abstract][Full Text] [Related]
8. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
Law J; Cowan MJ; Dvorak CC; Musick L; Long-Boyle JR; Baxter-Lowe LA; Horn B
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1656-63. PubMed ID: 22609040
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors.
Bitan M; Or R; Shapira MY; Aker M; Resnick IB; Ackerstein A; Samuel S; Elad S; Slavin S
Biol Blood Marrow Transplant; 2006 Jul; 12(7):712-8. PubMed ID: 16785060
[TBL] [Abstract][Full Text] [Related]
10. Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation.
Tan PL; Wagner JE; Auerbach AD; Defor TE; Slungaard A; Macmillan ML
Pediatr Blood Cancer; 2006 May; 46(5):630-6. PubMed ID: 16078221
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting the outcome of related allogeneic hematopoietic cell transplantation in patients with Fanconi Anemia.
Ayas M; Siddiqui K; Al-Jefri A; El-Solh H; Al-Ahmari A; Khairy A; Markiz S; Shahin H; Al-Musa A; Al-Seraihy A
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1599-603. PubMed ID: 24960628
[TBL] [Abstract][Full Text] [Related]
12. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
13. Single-Center Experience of Unrelated and Haploidentical Stem Cell Transplantation with TCRαβ and CD19 Depletion in Children with Primary Immunodeficiency Syndromes.
Balashov D; Shcherbina A; Maschan M; Trakhtman P; Skvortsova Y; Shelikhova L; Laberko A; Livshits A; Novichkova G; Maschan A
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1955-62. PubMed ID: 26187864
[TBL] [Abstract][Full Text] [Related]
14. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
[TBL] [Abstract][Full Text] [Related]
15. Successful T-cell-depleted, related haploidentical peripheral blood stem cell transplantation in a patient with Fanconi anaemia using a fludarabine-based preparative regimen without radiation.
Rossi G; Giorgiani G; Comoli P; Nobili B; Salvaneschi L; De Stefano P; Maccario R; Locatelli F
Bone Marrow Transplant; 2003 Mar; 31(6):437-40. PubMed ID: 12665837
[TBL] [Abstract][Full Text] [Related]
16. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide-based in vivo T-cell depletion for HLA-haploidentical transplantation in Fanconi anemia.
Thakar MS; Bonfim C; Sandmaier BM; O'Donnell P; Ribeiro L; Gooley T; Deeg HJ; Flowers ME; Pasquini R; Storb R; Woolfrey AE; Kiem HP
Pediatr Hematol Oncol; 2012 Sep; 29(6):568-78. PubMed ID: 22839094
[TBL] [Abstract][Full Text] [Related]
18. Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
Shin SH; Kim JH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Choi YS; Kim DY; Lee JH; Lee S; Kim HJ; Min CK; Lee JW; Lee KH; Min WS; Kim YJ; Lee JH
Biol Blood Marrow Transplant; 2015 Feb; 21(2):342-9. PubMed ID: 25459640
[TBL] [Abstract][Full Text] [Related]
19. Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.
Peterlin P; Delaunay J; Guillaume T; Gastinne T; Mahé B; Dubruille V; Blin N; Le Bourgeois A; Brissot E; Lodé L; Le Gouill S; Moreau P; Mohty M; Chevallier P
Biol Blood Marrow Transplant; 2015 Jan; 21(1):180-4. PubMed ID: 25175796
[TBL] [Abstract][Full Text] [Related]
20. Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.
Kharbanda S; Smith AR; Hutchinson SK; McKenna DH; Ball JB; Lamb LS; Agarwal R; Weinberg KI; Wagner JE
Biol Blood Marrow Transplant; 2014 Apr; 20(4):581-6. PubMed ID: 24370862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
